Cost-benefit analysis of ivermectin, permethrin and benzyl benzoate in the management of infantile and childhood scabies

Author： Elgart Mervyn L  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.9, 2003-09, pp. : 1521-1524

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Benefit Analysis of Amtolmetin-Guacil

By Belisari A.   Mantovani L.G.  

Clinical Drug Investigation, Vol. 21, Iss. 1, 2001-01 ,pp. : 47-58

Adis International

Access to resources Recommend Favorite

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

By Phillips Kathryn A   Veenstra David   Bebber Stephanie Van   Sakowski Julie  

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 231-239

Future Medicine

Access to resources Recommend Favorite

A cost–benefit analysis of chemotherapy for gastric cancer

By Galizia Eva   Berardi Rossana   Scartozzi Mario   Cascinu Stefano  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2109-2114

Informa Healthcare

Access to resources Recommend Favorite

Cost-benefit or cost-utility analysis?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 315, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

A Pharmacy-Based Health Promotion Programme in Hypertension: Cost-Benefit Analysis

By Côté I.  

PharmacoEconomics, Vol. 21, Iss. 6, 2003-01 ,pp. : 415-428

Adis International

Access to resources Recommend Favorite